HUTCHMED (China) Ltd (HCM) FinancialsHCMFinancialHUTCHMED (China) Ltd

HUTCHMED (China) Ltd (HCM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Immunology- Marketed products, accounting for 43.6% of total sales, equivalent to $121.43M. Other significant revenue streams include Other venture and Immunology- R&D. Understanding this composition is critical for investors evaluating how HCM navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, HUTCHMED (China) Ltd maintains a gross margin of 45.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 0.31%, while the net margin is 5.84%. These profitability ratios, combined with a Return on Equity (ROE) of 1.44%, provide a clear picture of how effectively HCM converts its operational activities into shareholder value.

In the context of the broader market, HCM competes directly with industry leaders such as JAZZ and VTRS. With a market capitalization of $2.16B, it holds a significant position in the sector. When comparing efficiency, HCM's gross margin of 45.32% stands against JAZZ's 76.30% and VTRS's 42.03%. Such benchmarking helps identify whether HUTCHMED (China) Ltd is trading at a premium or discount relative to its financial performance.

HUTCHMED reported a GAAP EPS of $0.02 for H1 2023, with revenue of $278.3 million, reflecting a modest year-over-year growth of 0.2%.